“Not all patients react the same way to medicines,” explains Glenn Gormley, global head of research and development at Daiichi Sankyo. “Whenever we can develop drugs that are focused on sub-populations [of patients where they are effective], which gets the right drug to the right patient at the right time, we should do so.”
Personalised medicine—creating more effective treatments by targeting them more precisely at the patients who are likely to benefit—is of growing importance to the life sciences sector. Survey respondents say that, on average, 20% of their current products could accurately be described as personalised medicines, a figure they expect to rise to 31% in the next three years. Research and development (R&D) processes are being shaped accordingly, with 77% of respondents saying that the identification of sub-groups of patients who respond better to treatments in clinical trials is a high or very high priority.